Imugene Limited (IMU) is an Australian immuno-oncology focused Biopharmaceutical Company developing range of new and novel immune therapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Lead products under development by the group are HER-Vaxx,PD1-Vaxx (formerly KEY-Vaxx),CF-33and B-Vax.
Imugene Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.imugene.com.
This a small cap company with market cap of 523 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is greater than both sector and market.
Dividend Growth Chart
The following chart shows you how imu dividend grows in the recent years.